Patents Assigned to Genentech
  • Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
    Patent number: 8987280
    Abstract: Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: March 24, 2015
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Jennafer Dotson, Tim Heffron, Alan Olivero, Daniel P. Sutherlin, Shumei Wang, Bing-Yan Zhu, Irina Chuckowree, Adrian Folkes, Nan Chi Wan
  • EGFR mutations
    Patent number: 8987266
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 24, 2015
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF
    Publication number: 20150080367
    Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
  • TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20150079081
    Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
    Type: Application
    Filed: October 27, 2014
    Publication date: March 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Jennafer Dotson, Robert Andrew Heald, Timothy Heffron, Graham Elgin Jones, Sussie Lerche Krintel, Neville James McLean, Chudi Ndubaku, Alan G. Olivero, Laurent Salphati, Lan Wang, BinQuing Wei
  • Inhibitors of IAP
    Patent number: 8980837
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: March 17, 2015
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
  • PROTEIN PURIFICATION
    Publication number: 20150072918
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Application
    Filed: March 18, 2014
    Publication date: March 12, 2015
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Anti-Angiogenesis Therapy for the Treatment of Previously Treated Breast Cancer
    Publication number: 20150071924
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Rajeshwari Swamy, Julie Hambleton
  • BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
    Publication number: 20150071910
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: March 12, 2014
    Publication date: March 12, 2015
    Applicant: Genentech, Inc.
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Anti-VEGF antibodies
    Patent number: 8975381
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 10, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA
    Publication number: 20150064178
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Applicant: Genentech, Inc.
    Inventors: Carlos BAIS, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
    Publication number: 20150065781
    Abstract: This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Applicant: Genentech, Inc.
    Inventors: Carlos BAIS, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • ANTI-C-MET-ANTIBODY FORMULATIONS
    Publication number: 20150064191
    Abstract: Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same.
    Type: Application
    Filed: November 5, 2014
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Barthelemy Demeule, Bruce Kabakoff, Jun Liu, Nicole Piros, Qing Zhu
  • ALKYNYL ALCOHOLS AND METHODS OF USE
    Publication number: 20150065482
    Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: August 22, 2014
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Nicole Blaquiere, Georgette Castanedo, Jianwen A. Feng, Baihua Hu, Steven Staben, Po-wai Yuen, Guosheng Wu, Jason Burch
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE
    Publication number: 20150064171
    Abstract: The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20150065388
    Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Mark DENNIS, Suzanna J. SCALES, Susan D. SPENCER, Yin ZHANG
  • METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS
    Publication number: 20150064186
    Abstract: Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.
    Type: Application
    Filed: April 6, 2012
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Dorothy French, Christian W. Siebel, Erik Huntzicker
  • Antibodies to hepatocyte growth factor activator
    Patent number: 8969528
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc
    Inventors: Daniel K. Kirchhofer, Yan Wu
  • Anti-CD22 antibodies and immunoconjugates and methods of use
    Patent number: 8968741
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20150056132
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.
    Type: Application
    Filed: May 27, 2014
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Jan Marik, Paul Polakis, Bonnee Rubinfeld, Simon Williams
  • DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
    Publication number: 20150056190
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Priti Hegde, Maike Schmidt, Ru-Fang Yeh